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Abstract
Background: Trans fatty acids (TFAs) have been hypothesised to influence breast cancer risk. However, relatively
few prospective studies have examined this relationship, and well-powered analyses according to hormone
receptor-defined molecular subtypes, menopausal status, and body size have rarely been conducted.
Methods: In the European Prospective Investigation into Cancer and Nutrition (EPIC), we investigated the
associations between dietary intakes of TFAs (industrial trans fatty acids [ITFAs] and ruminant trans fatty acids
[RTFAs]) and breast cancer risk among 318,607 women. Multivariable hazard ratios (HRs) and 95% confidence
intervals (CIs) were estimated using Cox proportional hazards models, adjusted for other breast cancer risk factors.
Results: After a median follow-up of 8.1 years, 13,241 breast cancer cases occurred. In the multivariable-adjusted
model, higher total ITFA intake was associated with elevated breast cancer risk (HR for highest vs lowest quintile,
1.14, 95% CI 1.06–1.23; P trend = 0.001). A similar positive association was found between intake of elaidic acid, the
predominant ITFA, and breast cancer risk (HR for highest vs lowest quintile, 1.14, 95% CI 1.06–1.23; P trend = 0.001).
Intake of total RTFAs was also associated with higher breast cancer risk (HR for highest vs lowest quintile, 1.09, 95%
CI 1.01–1.17; P trend = 0.015). For individual RTFAs, we found positive associations with breast cancer risk for dietary
intakes of two strongly correlated fatty acids (Spearman correlation r = 0.77), conjugated linoleic acid (HR for highest
vs lowest quintile, 1.11, 95% CI 1.03–1.20; P trend = 0.001) and palmitelaidic acid (HR for highest vs lowest quintile,
1.08, 95% CI 1.01–1.16; P trend = 0.028). Similar associations were found for total ITFAs and RTFAs with breast cancer
risk according to menopausal status, body mass index, and breast cancer subtypes.
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Conclusions: These results support the hypothesis that higher dietary intakes of ITFAs, in particular elaidic acid, are
associated with elevated breast cancer risk. Due to the high correlation between conjugated linoleic acid and
palmitelaidic acid, we were unable to disentangle the positive associations found for these fatty acids with breast
cancer risk. Further mechanistic studies are needed to identify biological pathways that may underlie these
associations.
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Background
Breast cancer is the most commonly diagnosed malig-
nancy among women with over 2 million cases diag-
nosed globally in 2018 [1]. Despite being extensively
studied, few established dietary risk factors for breast
cancer have been identified [2]. The association between
dietary fat intake and breast cancer risk has been a
source of controversy with conflicting results reported in
past decades [3–5]. Limited epidemiological evidence
suggests that rather than total fat intake, types of fatty
acids may diversely influence breast cancer risk [6, 7].
Trans fatty acids (TFAs) have been hypothesised to in-
fluence breast cancer risk [8]. TFAs can come from in-
dustrial processes generating industrial trans fatty acids
(ITFAs), used in frying oils, margarines, and bakery
products, or from ruminant trans fatty acids (RTFAs),
from dairy and meat sources. Dietary intake of TFAs has
been linked in experimental and observational studies to
adiposity, insulin resistance, and systemic inflammation
[9, 10], all risk factors for breast cancer [2, 11, 12]. How-
ever, the few prospective studies that have examined
how dietary intakes of TFAs relate to breast cancer risk
have generally reported null results [13]. These prior
prospective studies were usually of relatively small size
and generally did not examine the associations between
TFAs and hormone receptor-defined molecular subtypes
of breast cancer. Recently, in a case–control study
nested within the European Prospective Investigation
into Cancer and Nutrition Study (EPIC), higher plasma
phospholipid levels of ITFAs were associated with a
raised risk of oestrogen receptor-negative (ER−) breast
cancer, but not overall breast cancer risk [14]. This re-
sult suggests that the relation between TFAs and breast
cancer may differ according to hormone receptor sub-
type. A comprehensive and sufficiently powered examin-
ation of how dietary intakes of TFAs are associated with
overall breast cancer and its molecular-defined subtypes
is therefore warranted.
We investigated the association between dietary in-
takes of TFAs (ITFAs and RTFAs) with breast cancer
risk in the EPIC study, an ongoing multinational cohort
with more than 318,000 women. The large number of
incident breast cancer cases (> 13,200 cases) affords high
statistical power to examine the TFA associations across




EPIC is a multicentre cohort of 521,330 participants
(mostly aged 35 years and older) who were recruited be-
tween 1992 and 2000, predominantly from the general
population of 10 European countries (Denmark, France,
Germany, Greece, Italy, Netherlands, Norway, Spain,
Sweden, and the UK) [15, 16]. Written informed consent
was provided by all study participants. Ethical approval
for this study was provided by the International Agency
for Research on Cancer and the institutional review
boards of the local participating EPIC centres. The
present analysis excluded men (n = 157,994), women
from Greece (n = 15,239; excluded due to an ongoing
data protection issue), women with prevalent cancers at
any site (n = 19,853), those with missing diagnosis or
censoring date (n = 2892), and those with missing dietary
or lifestyle information (n = 6745). Our analysis therefore
included 318,607 women.
Assessment of dietary intake and other covariates
Dietary intake was assessed during the baseline enrol-
ment visit (1992–2000) by country-specific instruments
that were developed and validated within the various
source populations in EPIC [15, 16]. Self-administered
questionnaires were used in all centres, except in Spain
and Ragusa (Italy), where data were collected during per-
sonal interviews. In Malmo (Sweden), a combined semi-
quantitative food frequency questionnaire and 7-day
dietary diary and diet interview was used. In order to es-
timate the intakes of individual fatty acids, the EPIC Nu-
trient Database (ENDB) was matched with the National
Nutrient Database for Standard Reference of the United
States (NNDSR; developed at the United States Depart-
ment of Agriculture [USDA]) [17, 18]. To date, most of
the national food composition databases of the ten re-
spective EPIC countries do not contain nutritional
values for specific dietary components such as fatty acid
isomers that have been included in the NNDSR food
composition tables. In addition, the USDA database in-
cludes a large number of food and recipe items from
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various countries and eating cultures (> 8000 food items)
and used standard reference analytical methods to ob-
tain the respective nutritional values [19]. The USDA
database was matched with the EPIC food list to extend
the ENDB database with extra food components, includ-
ing dietary fatty acids. Specific foods and recipes that
were not included in the USDA were decomposed into
ingredients that were available in the USDA table. The
fatty acid intakes reported in this manuscript were ob-
tained through this extra USDA matching, and their
quality has been confirmed through different quality
controls. The first type of quality control includes the
double-checking of the work performed by the three die-
titians among each other. The second type of quality
control includes the comparison between the nutrient
values obtained through the ENDB procedures (match-
ing with the national food composition databases) and
this new USDA matching for the 28 food components
that had already been matched with the EPIC food con-
sumption data. The third type of quality control includes
the comparison of the nutrients included in the ex-
tended EPIC database with nutritional biomarkers avail-
able in the nested case–control studies in EPIC. All
these quality controls confirmed the validity of the data
on fatty acids and their different isomers included in this
manuscript (e.g. the correlation between TFAs derived
from the dietary questionnaires and from plasma phos-
pholipids was 0.53). ITFAs included elaidic acid and its
isomers. For RTFA, the individual fatty acids included
were palmiteaidic acid, conjugated linoleic acid, and vac-
cenic acid. Palmitelaidic acid could also be classified as
an ITFA; however, in our population, its main sources
were from dairy products.
Lifestyle questionnaires, administered at recruitment,
were used as a source of information on educational at-
tainment, smoking habits, alcohol intake, physical activ-
ity, reproductive and menstrual characteristics, and
other variables.
Follow-up and ascertainment of breast cancer
Incident cancer cases were identified using population
cancer registries in Denmark, Italy, the Netherlands,
Norway, Spain, Sweden, and the UK. In France and
Germany, cancer cases were identified during follow-up
from a combination of sources including health insur-
ance records, cancer and pathology registries, and active
follow-up directly through study participants or their
next of kin. Incident breast cancer cases included inva-
sive epithelial tumours at the primary site. Breast cancer
cases were classified as ICD-10 code C50. Data on ER
status was available for 9500 cases (1716 ER− and 7784
ER+) and on progesterone receptor (PR) for 7973 cases
(2708 PR− and 5265 PR+). When stratified by positive
or negative receptor status, there were 1259 ER− and PR
− cases and 4830 ER+ and PR+ breast cancer cases. Im-
munohistochemical measurements of ER and PR expres-
sion were carried out in each EPIC centre. The following
criteria were applied for a positive receptor status: ≥ 10%
cells stained, any ‘plus system’ description, ≥ 20 fmol/
mg, an Allred score of > 3, and IRS ≥ 2, or an H-score ≥
10. Participants with ambiguous positive hormone recep-
tor scores were excluded from analyses involving tumour
receptor status (10% cells stained, = 20 fmol/mg, Allred
score = 3, IRS ‘1–2’ or 2, H-score = e10). Further stratifi-
cation by compilation of human epidermal growth factor
receptor 2 (HER2) was made delimiting four categories:
(1) ER− and PR− and HER2−, with 412 cases; (2) ER+
and PR+ and HER2+, with 349 cases; (3) ER− and PR−
and HER2+, with 248 cases; and (4) ER+ and PR+ and
HER2−, with 2174 cases.
Statistical analyses
Hazard ratios (HRs) and 95% confidence intervals (CIs)
for breast cancer risk were estimated using Cox propor-
tional hazards regression models. Age was used as the
time-scale in all models. Time at entry was age at re-
cruitment. Exit time was age at whichever of the follow-
ing came first: cancer diagnosis (except non-melanoma
skin cancer), death, emigration, or last follow-up. Models
were stratified by age at recruitment in 1-year categories
and study centre.
Dietary estimates of TFAs were classified into quintiles
or quartiles (for the analyses by hormonal receptor sub-
types) based on the distribution of dietary intakes of
fatty acid levels in all women. Statistical tests for trend
were calculated using the ordinal quintile/quartile vari-
able entered into the models as a continuous variable
(primary method) and by using the quintile median
values as a continuous variable (sensitivity analysis).
Multivariable models were adjusted for the following
variables, all assessed at recruitment: height (cm; con-
tinuous), education level (none and primary, technical or
professional, secondary, higher education, and missing/
unknown), body mass index (BMI, kg/m2; continuous),
physical activity index (inactive, moderately inactive,
moderately active, active and missing/unknown), energy
intake (kcal/day; continuous), age at first birth and parity
combined (nulliparous, first birth before age 30 years, 1–
2 children; first birth before age 30 years, ≥ 3 children;
first birth at age or after age of 30 years and missing/un-
known), alcohol consumption (g/day; continuous),
menopausal status (premenopausal, postmenopausal,
perimenopausal, surgical postmenopausal bilateral ovari-
ectomy), and smoking status (never, former, current,
missing/unknown). Additional adjustment for meno-
pausal hormone replacement therapy, age at menopause,
breastfeeding, oral contraceptive use, and family history
of breast cancer resulted in virtually unchanged HR
Matta et al. BMC Medicine           (2021) 19:81 Page 3 of 11
estimates. False discovery rate correction was computed
(Q value) for the overall breast cancer multivariable
models using the Benjamini–Hochberg method [20]. In
sensitivity analyses, we adjusted for total energy intake
using the residuals method; mutually adjusted the total
ITFA and RTFA models; adjusted the total ITFA and
RTFA multivariable models for dietary intakes of satu-
rated fatty acids (SFA), monounsaturated fatty acids
(MUFAs), and polyunsaturated fatty acids (PUFA); and
adjusted the total ITFA and RTFA multivariable models
for the Mediterranean diet and the World Cancer Re-
search Fund (WCRF) diet scores.
Analyses were also conducted according to hormonal
receptor status (ER− and PR−, ER+ and PR+, ER, and
PR) leading to another stratification compiling HER2
with four categories (ER− and PR− and HER2−; ER+
and PR+ and HER2+; ER− and PR− and HER2+; ER+
and PR+ and HER2−). Tests of heterogeneity of associa-
tions were carried out based on chi-square statistics, cal-
culated as the deviation of logistic β-coefficients
observed in each of the breast cancer subgroups relative
to the overall β-coefficients. We also examined the asso-
ciation between dietary intakes of TFAs and breast can-
cer risk by menopausal status (premenopausal,
postmenopausal) and BMI group (normal, overweight,
obese), as prior evidence suggests that the fatty acid and
breast cancer relationship may differ according to body
size [21]. Interaction terms (multiplicative scale) between
these variables and dietary intakes of TFAs were in-
cluded in separate models, and the statistical significance
of the cross-product terms was evaluated using likeli-
hood ratio tests. Heterogeneity across countries was ex-
plored using a meta-analytic approach [22].
Statistical tests were all two-sided, and a P value of <
0.05 was considered statistically significant. Analyses
were conducted using Stata version 14.2 (StataCorp,
College Station, TX, USA).
Results
During a median follow-up of 8.1 years, 13,241 malig-
nant breast cancer cases were diagnosed. Baseline char-
acteristics of study participants are summarised in
Table 1 by dietary intakes of total ITFA and RTFA and
for breast cancer cases and non-cases in Additional file 1:
Table S1. Compared with the non-cases, breast cancer
cases were older with a greater proportion of postmeno-
pausal women. Breast cancer cases reported higher alco-
hol consumption, were less physically active, and were
more likely to have used hormone replacement therapy.
The Spearman correlation matrix for dietary intake of
the different TFAs is presented in Additional file 1:
Table S2. Modest correlations were found between indi-
vidual TFAs, with the exception of a high correlation
(r = 0.77) found between the RTFAs, palmitelaidic acid,
and conjugated linoleic acid. Food group sources of con-
jugated linoleic acid and elaidic acid (the predominant
ITFA) are presented in Additional file 1: Table S3.
Dietary industrial trans fatty acid (ITFA) intake and breast
cancer risk
In the multivariable model, higher dietary intake of total
ITFAs was associated with elevated breast cancer risk
(HR for highest vs lowest quintile, 1.14, 95% CI 1.06–
1.23; P trend = 0.001) (Table 2). Higher breast cancer
risk for total ITFA intake was found from the second
quintile onwards (intakes ≥ 0.54 g/day). For individual
ITFAs, a positive association was found between dietary
intakes of elaidic acid and breast cancer risk (HR for
highest vs lowest quintile, 1.14, 95% CI 1.06–1.23; P
trend = 0.001) (Table 2). In analyses by tumour hormo-
nal receptor status, there was little evidence of statistical
heterogeneity (Table 3; Additional file 1: Tables S4-S6),
although statistically significant positive associations
were found for elaidic acid and total ITFAs with ER+/
PR+ breast cancer (total ITFAs: HR for highest vs lowest
quartile, 1.14, 95% CI 1.02–1.28; P trend = 0.009; elaidic
acid: HR for highest vs lowest quartile, 1.14, 95% CI
1.01–1.27; P trend = 0.007), but not for ER−/PR− breast
cancer (total ITFAs: HR for highest vs lowest quartile,
1.08, 95% CI 0.87−1.33; P trend = 0.48; elaidic acid: HR
for highest vs lowest quartile, 1.08, 95% CI 0.87−1.34; P
trend = 0.49) (Table 3). Similarly, when human HER2
status was further taken into consideration, more con-
sistent positive associations were found for ITFAs with
ER+/PR+/HER2− breast cancer than the ER+/PR+/
HER2+ subtype (Additional file 1: Table S6).
Dietary ruminant trans fatty acid (RTFA) intake and breast
cancer risk
In the multivariable model, dietary intake of total RTFA
was positively associated with breast cancer risk (HR for
highest vs lowest quintile, 1.09, 95% CI 1.01–1.17; P
trend = 0.015) (Table 2). Among individual RTFAs, higher
dietary intake of palmitelaidic acid (HR for highest vs low-
est quintile, 1.08, 95% CI 1.01–1.16; P trend = 0.028) and
conjugated linoleic acid was associated with greater breast
cancer risk (HR for highest vs lowest quintile, 1.11, 95%
CI 1.03–1.20; P trend = 0.001). No association was found
between intake of vaccenic acid and breast cancer risk
(HR for highest vs lowest quintiles, 1.02, 95% CI 0.95–
1.10; P trend = 0.51). For RTFAs, there was little evidence
of heterogeneity by hormonal receptor status (Table 3 and
Additional file 1: Tables S4-S6).
Subgroup and sensitivity analyses
In subgroup analyses, there was no heterogeneity for the
associations between total ITFAs and RTFAs with breast
cancer risk by BMI group, menopausal status (P
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heterogeneities ≥ 0.18; Additional file 1: Tables S7
and S8), and country (I2 = 0%, P heterogeneities > 0.9;
Additional file 1: Figures S1 and S2). Similar associations
were found when we adjusted for total energy intake
using the residuals method (Additional file 1: Table
S9); mutually adjusted the total ITFA and RTFA
models (Additional file 1: Table S10); additionally
adjusted the total ITFA and RTFA models for
dietary intakes of SFA, MUFA, and PUFA (Add-
itional file 1: Table S11); and additionally adjusted
the total ITFA and RTFA models for the Mediterra-
nean or WCRF diet scores (Additional file 1: Table
S12). Similar tests for trend across dietary intake
groups were found when the quintile median values
were used as a continuous variable (Additional file 1:
Table S13).
Table 1 Characteristics of study participants by dietary intake of total industrial trans fatty acid and total ruminant trans fatty acid
Total industrial trans fatty acid intake, median
(IQR)
Total ruminant trans fatty acid intake, median
(IQR)
Quintile 1 Quintile 5 Quintile 1 Quintile 5
Age at recruitment, years 51.2 (44.0–57.2) 51.2 (43.8–58.5) 53.0 (48.3–59.1) 50.1 (44.8–57.1)
Follow-up, years 14.9 (13.8–16.3) 15.9 (14.1–17.3) 16.1 (14.1–17.5) 14.8 (12.2–15.2)
Weight, kg 63.5 (57.0–71.1) 64.1 (58.0–72.0) 66 (59.5–74.0) 61.4 (55.7–68.6)
Height, cm 159.5 (155.0–164) 164 (160.0–168.1) 163.0 (158.2–167.5) 162.4 (158.2–167.0)
Body mass index (BMI), kg/m2 24.9 (22.3–28.2) 23.8 (21.6–26.6) 24.8 (22.4–28.0) 23.1 (21.1–25.8)
Number of full-term pregnancies 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
Ever use oral contraceptives (%)
Yes 31,013 (48.8) 36,167 (61.8) 31,779 (53.1) 40,973 (65.0)
Age at first birth combinations (%)
Nulliparous 8374 (13.1) 9642 (15.1) 7700 (12.1) 9773 (15.3)
Age at first birth < 30 (1–2 children) 29,686 (46.6) 24,325 (38.1) 27,918 (43.8) 28,447 (44.6)
Age at first birth < 30 (3< children) 16,456 (25.8) 15,082 (23.6) 17,540 (27.5) 14,536 (22.8)
Age at first birth ≥ 30 7486 (11.7) 7003 (10.9) 5672 (8.9) 7655 (12.0)
Ever use hormone replacement therapy for menopause (%)
Yes 13,345 (48.9) 15,832 (54.9) 18,372 (54.9) 16,432 (65.2)
Ever breastfed (%)
Yes 44,205 (71.8) 37,254 (74.0) 43,305 (78.9) 39,427 (66.6)
Menopausal status (%)
Premenopausal 24,076 (37.7) 21,332 (33.4) 15,837 (24.8) 23,139 (36.3)
Postmenopausal 26,710 (41.9) 28,886 (45.3) 34,109 (53.5) 26,157 (41.0)
Age at menopause, years 48.6 (46.0–52.0) 48.6 (46.0–52.0) 48.7 (46.0–52.0) 48.9 (46.0–52.0)
Alcohol intake (g/day)
None 16,483 (25.8) 8166 (12.8) 12,376 (19.4) 7330 (11.5)
> 60 g/day 7193 (11.2) 2908 (4.5) 5138 (8.0) 5521 (8.6)
Total dietary energy intake (kcal/day) 1779 (1835–2527) 2155 (1835–2527) 1667 (1370–2008) 2305 (1960–2700)
Education status (%)
None and primary school 29,078 (45.6) 15,907 (24.9) 25,398 (39.8) 10,750 (16.8)
Higher education 12,360 (19.4) 12,291 (19.2) 9581 (15.0) 20,510 (32.2)
Physical activity (%)
Inactive 20,789 (32.6) 11,591 (18.1) 13,776 (21.6) 13,467 (21.1)
Active 6703 (10.5) 11,457 (17.9) 12,725 (19.9) 7922 (12.4)
Smoking status (%)
Never 38,253 (60.0) 32,130 (50.4) 33,578 (52.6) 38,912 (61.1)
Current 12,300 (19.3) 15,844 (24.8) 15,468 (24.2) 9095 (14.2)
IQR interquartile range
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HR (95% CI) HR (95% CI)
Total industrial trans fatty acidsa Q1 2324/63,722 < 544 1 (reference) 1 (reference)
Q2 2674/63,721 544–< 973 1.10 (1.04–1.17) 1.10 (1.04–1.17)
Q3 2692/63,722 973–< 1520 1.11 (1.04–1.18) 1.12 (1.05–1.20)
Q4 2780/63,721 1520–< 2535 1.13 (1.06–1.21) 1.15 (1.07–1.23)
Q5 2771/63,721 ≥ 2535 1.11 (1.04–1.19) 1.14 (1.06–1.23)
P trend 0.009 0.001
Q value 0.002
Elaidic acid Q1 2323/63,722 < 506 1 (reference) 1 (reference)
Q2 2651/63,721 506–< 924 1.09 (1.03–1.16) 1.10 (1.03–1.17)
Q3 2719/63,722 924–< 1455 1.12 (1.05–1.19) 1.13 (1.06–1.20)
Q4 2771/63,721 1455–< 2470 1.14 (1.07–1.22) 1.16 (1.08–1.24)
Q5 2777/63,721 ≥ 2470 1.11 (1.04–1.19) 1.14 (1.06–1.23)
P trend 0.005 0.001
Q value 0.002
Total ruminant trans fatty acidsb Q1 2961/63,724 < 13.58 1 (reference) 1 (reference)
Q2 2406/63,726 13.58–< 26.41 1.04 (0.98–1.11) 1.03 (0.97–1.10)
Q3 2499/63,715 26.41–< 49.03 1.05 (0.98–1.12) 1.03 (0.97–1.10)
Q4 2629/63,721 49.03–< 86.31 1.10 (1.03–1.18) 1.08 (1.01–1.16)
Q5 2746/63,721 ≥ 86.31 1.11 (1.04–1.19) 1.09 (1.01–1.17)
P trend 0.001 0.015
Q value 0.022
Palmitelaidic acid Q1 3031/63,722 < 1.28 1 (reference) 1 (reference)
Q2 2698/63,698 1.28–< 2.98 1.04 (0.98–1.10) 1.03 (0.97–1.09)
Q3 2389/63,723 2.98–< 6.56 1.02 (0.96–1.09) 1.01 (0.95–1.08)
Q4 2473/63,715 6.56–< 18.01 1.08 (1.01–1.15) 1.07 (1.00–1.14)
Q5 2650/63,721 ≥ 18.01 1.09 (1.02–1.17) 1.08 (1.01–1.16)
P trend 0.007 0.028
Q value 0.034
Conjugated linoleic acid Q1 2953/63,725 < 10.18 1 (reference) 1 (reference)
Q2 2394/63,720 10.18–< 19.25 1.03 (0.97–1.09) 1.02 (0.96–1.09)
Q3 2494/63,720 19.25–< 35.63 1.07 (1.00–1.14) 1.05 (0.99–1.13)
Q4 2632/63,721 35.63–< 65.32 1.13 (1.05–1.21) 1.11 (1.03–1.19)
Q5 2768/63,721 ≥ 65.32 1.14 (1.06–1.22) 1.11 (1.03–1.20)
P trend < 0.001 0.001
Q value 0.002
Vaccenic acid Q1/Q2c 5701/130,242 < 0.07 1 (reference) 1 (reference)
Q3 2434/60,976 0.07–< 0.08 1.03 (0.96–1.11) 1.03 (0.96–1.11)
Q4 2646/63,675 0.08–< 2.24 1.04 (0.97–1.11) 1.03 (0.96–1.11)
Q5 2460/63,714 ≥ 2.24 1.04 (0.96–1.12) 1.02 (0.95–1.10)
P trend 0.34 0.51
Q value 0.51
HR hazard ratio, CI confidence interval
§Stratified by study centre and age (in 1-year categories)
†Stratified by study centre and age (in 1-year categories) and adjusted for total energy intake (kcal/day; continuous), body mass index (kg/m2; continuous), height (cm;
continuous), alcohol consumption (g/day; continuous), education level (none and primary, technical or professional and secondary, higher education), age at first birth
and parity combined (nulliparous, first birth before age 30 years, 1–2 children; first birth before age 30 years, ≥ 3 children; first birth ≥ 30 years), physical activity
(inactive, moderately inactive, moderately active, and active), menopausal status (premenopausal, postmenopausal, perimenopausal, surgical postmenopausal bilateral
ovariectomy), and smoking status (never, former, current smoker, unknown)
aTotal industrial trans fatty acids included 18:1n-9 t, 18:2n-6tt
bTotal ruminant trans fatty acids included 16:1n-9 t, 18:1n-7t, conjugated linoleic acid
cQuintiles 1 and 2 merged due to extreme low intake values in these groups
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Discussion
In this large multinational European study, we found
that higher dietary intakes of total ITFAs and RTFAs
were associated with greater breast cancer risk. For
ITFAs, a positive association was found for intake of
elaidic acid, with no heterogeneity found across breast
cancer hormone receptor-defined molecular subtypes.
For RTFAs, higher intake of dietary conjugated linoleic
acid was unexpectedly associated with greater breast
cancer risk, although intake of conjugated linoleic acid
in our population was strongly correlated with intake of
palmitelaidic acid, which was also positively associated
Table 3 Associations between dietary intake of trans fatty acids and molecular subtypes of breast cancer risk





Total industrial trans fatty acidsa Q1 1 (reference) 1 (reference)
Q2 0.99 (0.84–1.18) 1.13 (1.04–1.23)
Q3 1.02 (0.85–1.22) 1.18 (1.07–1.29)
Q4 1.08 (0.87–1.33) 1.14 (1.02–1.28)
P trend 0.48 0.009 0.55
Elaidic acid Q1 1 (reference) 1 (reference)
Q2 0.99 (0.83–1.17) 1.12 (1.03–1.22)
Q3 1.01 (0.84–1.21) 1.19 (1.08–1.31)
Q4 1.08 (0.87–1.34) 1.14 (1.01–1.27)
P trend 0.49 0.007 0.52
Total ruminant trans fatty acidsb Q1 1 (reference) 1 (reference)
Q2 1.08 (0.89–1.32) 1.02 (0.92–1.13)
Q3 1.13 (0.92–1.39) 1.01 (0.91–1.12)
Q4 1.07 (0.85–1.34) 1.11 (0.99–1.25)
P trend 0.63 0.055 0.64
Palmitelaidic acid Q1 1 (reference) 1 (reference)
Q2 0.91 (0.76–1.09) 1.01 (0.92–1.11)
Q3 1.05 (0.86–1.28) 1.07 (0.96–1.18)
Q4 1.03 (0.84–1.26) 1.09 (0.98–1.21)
P trend 0.46 0.07 0.84
Conjugated linoleic acid Q1 1 (reference) 1 (reference)
Q2 1.09 (0.90–1.33) 0.99 (0.89–1.09)
Q3 1.11 (0.90–1.38) 1.01 (0.90–1.12)
Q4 1.12 (0.89–1.41) 1.10 (0.98–1.24)
P trend 0.38 0.056 0.90
Vaccenic acid Q1 1 (reference) 1 (reference)
Q2 0.98 (0.76–1.26) 1.08 (0.94–1.23)
Q3 0.90 (0.71–1.14) 1.14 (1.01–1.29)
Q4 0.92 (0.72–1.17) 1.09 (0.96–1.23)
P trend 0.39 0.26 0.20
Stratified by study centre and age (in 1-year categories) and adjusted for total energy intake (kcal/day; continuous), body mass index (kg/m2; continuous), height
(cm; continuous), alcohol consumption (g/day; continuous), education level (none and primary, technical or professional and secondary, higher education), age at
first birth and parity combined (nulliparous, first birth before age 30 years, 1–2 children; first birth before age 30 years, ≥ 3 children; first birth ≥ 30 years), physical
activity (inactive, moderately inactive, moderately active, and active), menopausal status (premenopausal, postmenopausal, perimenopausal, surgical
postmenopausal bilateral ovariectomy), and smoking status (never, former, current smoker, unknown)
ER− and PR− oestrogen receptor-negative/progesterone receptor-negative, ER+ and PR+ oestrogen receptor-positive and progesterone receptor-positive, HR
hazard ratio, CI confidence interval
aTotal industrial trans fatty acids included 18:1n-9t, 18:2n-6tt
bTotal ruminant trans fatty acids included 16:1n-9t, 18:1n-7t, conjugated linoleic acid
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with breast cancer risk. For all TFAs, similar associations
with breast cancer risk were found according to meno-
pausal status and BMI group.
To our knowledge, this is the first prospective study to
find that higher dietary intake of ITFAs was associated
with raised breast cancer risk. We found a similar mag-
nitude positive association for dietary intake of elaidic
acid, the predominant ITFA. Previously, an analysis in
the VITamins And Lifestyle (VITAL) cohort reported a
suggestive positive association for the intake of elaidic
acid that did not reach the threshold of statistical signifi-
cance [23], while other perspective studies found no evi-
dence of an association between ITFA intake and risk of
breast cancer [24, 25]. Our positive association for diet-
ary intake of ITFAs with overall breast cancer risk is
concordant with findings from a nested case–control
study in the French E3N study, in which higher serum
phospholipid ITFA levels were associated with elevated
breast cancer risk (odds ratio [OR] for highest vs lowest
quintile, 1.75, 95% CI 1.08–2.83; P trend = 0.018) [26]. In
another previous analysis in the EPIC study, a similar
positive association was found between serum ITFA
levels and breast cancer risk, but only for ER− tumours
(OR for highest vs lowest tertile, 2.01, 95% CI 1.03–3.90;
P trend = 0.047) [14]. In contrast, we found no hetero-
geneity in the association between total ITFA intake and
breast cancer risk according to hormone receptor-
defined molecular subtypes. Collectively, evidence from
most of these European studies supports a positive rela-
tionship between dietary intakes of ITFAs and breast
cancer risk. However, further studies are required to
understand the heterogeneity of this relationship across
molecular subtypes of breast cancer defined by tumour
hormonal receptor status.
Prior experimental evidence linking ITFAs with breast
cancer is limited. Elaidic acid has been shown to modu-
late hepatic lipogenesis through upregulating the
SREBP-1 pathway [27]. However, further mechanistic
studies are needed to better understand the possible det-
rimental health effects of ITFAs in relation to breast
cancer development.
ITFAs, created when fats and oils are partially hydro-
genated during industrial processing, are found in fast
foods, industrially produced products and snacks, deep
fried foods, baked goods, and ultra-processed foods.
Since the 1990s, ITFA content in popular food products
found in Europe has declined [28, 29], and many coun-
tries do not limit their content in food products [30]. In
2019, the European Union (EU) set new recommenda-
tions for ITFA intake, in accordance with those from the
World Health Organization (WHO), for foods to be
largely free of industrial trans fats by 2023 [31, 32].
These recommendations set a threshold of no more than
2 g per 100 g on ITFA products, and country members
have until 2021 to implement these changes [33]. It is of
note, however, that in our data, raised breast cancer risk
was found at relatively low total dietary ITFA intake
levels (≥ 0.54 g per day), when compared with partici-
pants with intake below this level. Consequently, adher-
ence to the new EU regulations on IFTA content of
foods may have minimal impact on the dietary ITFA in-
take and breast cancer relationship. However, further
high-quality studies are required to confirm the positive
association we found between dietary ITFA intake and
breast cancer risk.
We also found an unexpected association between
higher dietary intake of total RTFAs and elevated breast
cancer risk. This result was driven by positive associa-
tions of similar magnitude for conjugated linoleic acid
and palmitelaidic acid, with vaccenic acid being unre-
lated to breast cancer risk. Conjugated linoleic acid com-
prises a family of positional and geometric isomers of
linoleic acid and is mostly found in meat and dairy prod-
ucts derived from ruminants. Several experimental stud-
ies have demonstrated protective effects of conjugated
linoleic acid in the mammary gland at pharmacological
doses [34–38]. In rodent models, conjugated linoleic
acid had anti-proliferative effects in mammary tumori-
genesis [37]. While in human breast tissue and in vitro
studies, conjugated linoleic acid has been shown to in-
duce apoptosis and inhibit breast cancer cellular prolif-
eration via ER-mediated pathways [35, 38]. Finally,
specific conjugated linoleic acid isomers have been
shown to regulate mammary tumour growth, inducing
expression of apoptotic genes and inhibiting cellular
growth [34]. This experimental evidence, however, is not
supported by prospective epidemiological evidence. Ana-
lyses in the Swedish Mammography Cohort and Mel-
bourne Collaborative Cohort Study found no association
between dietary intake of conjugated linoleic acid and
breast cancer risk [39, 40]. An analysis in the
Netherlands Cohort Study on Diet and Cancer, similar
to our result, found a positive association between con-
jugated linoleic acid and breast cancer risk (relative risk
for highest vs lowest quintile, 1.24, 95% CI 0.91–1.69; P
trend = 0.02) [41]. In our data, dietary intake of conju-
gated linoleic acid was strongly correlated with intake of
palmitelaidic acid (Spearman correlation r = 0.77), an
RTFA sourced from hydrogenated vegetable oils and
dairy foods, for which we also found a positive associ-
ation with breast cancer risk; consequently, we are un-
able to separate the positive associations found for these
fatty acids. Overall, prospective epidemiological data
provide little evidence to support the anti-tumorigenic
effects of conjugated linoleic acid on breast cancer devel-
opment found in experimental studies.
This was the largest study to comprehensively examine
the association between dietary intakes of TFAs and
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breast cancer. The large sample size and high-quality
epidemiological and clinical data allowed us to exam-
ine the association by tumour molecular subtypes and
according to menopausal status and BMI group. A
limitation of our study is that dietary intake was mea-
sured once at baseline (using questionnaires) and con-
sequently may be subject to random measurement
error and not reflective of longer-term habits; any
such bias would likely lead to an underestimation of
true associations. In addition, like all studies using
self-reported dietary intake assessments, the estimated
fatty acid intakes may be prone to respondent bias
and measurement error related to data included in
food composition tables. However, as outlined above,
we adopted several quality control measures for the
matching procedure with the USDA database [42]. An
additional limitation was that despite our comprehen-
sive analyses according to tumour molecular subtypes
we lacked data to examine the dietary TFA intake
and breast cancer association for luminal A and lu-
minal B tumours. Another possible limitation of our
study is that dietary conjugated linoleic acid supple-
ment use data was not collected so our analyses were
limited to dietary intakes only.
Conclusion
Our findings support the hypothesis that dietary in-
take of ITFAs, in particular elaidic acid, may increase
breast cancer risk. Although we observed positive re-
lationships for intake of both conjugated linoleic acid
and palmitelaidic acid with breast cancer risk, the
high correlation between these fatty acids means we
were unable to differentiate these associations. Further
mechanistic studies are needed to identify biological
pathways that may underlie these associations. If our
results are confirmed in future studies, the current
EU and WHO limits for acceptable thresholds for in-
dustrial trans fats in foods may need to be revised to
safeguard public health [31, 32]. However, given the
results of our study, as well as the accumulating evi-
dence of their deleterious effects on health, recom-
mendations to limit as much as possible human
consumption of industrial trans fats should be consid-
ered globally.
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